Pharmacogenomics of HIV therapy: Summary of a workshop sponsored by the National Institute of allergy and infectious diseases

David Haas, Daniel Kuritzkes, Marylyn Ritchie, Shashi Amur, Brian Gage, Gary Maartens, Dan Masys, Jacques Fellay, Elizabeth Phillips, Heather Ribaudo, Kenneth Freedberg, Christos Petropoulos, Teri Manolio, Roy Gulick, Richard Haubrich, Peter Kim, Marjorie Dehlinger, Rahel Abebe, Amalio Telenti

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


Approximately 1 million people in the United States and over 30 million worldwide are living with human immunodefi ciency virus type 1 (HIV-1). While mortality from untreated infection approaches 100%, survival improves markedly with use of contemporary antiretroviral therapies (ART). In the United States, 25 drugs are approved for treating HIV-1, and increasing numbers are available in resource-limited countries. Safe and effective ART is a cornerstone in the global struggle against the acquired immunodefi ciency syndrome. Variable responses to ART are due at least in part to human genetic variants that affect drug metabolism, drug disposition, and off-site drug targets. Defi ning effects of human genetic variants on HIV treatment toxicity, effi cacy, and pharmacokinetics has far-reaching implications. In 2010, the National Institute of Allergy and Infectious Diseases sponsored a workshopentitled,Pharmacogenomics A Path Towards Personalized HIV Care. This article summarizes workshop objectives, presentations, discussions, and recommendations derived from this meeting.

Original languageEnglish
Pages (from-to)277-285
Number of pages9
JournalHIV Clinical Trials
Issue number5
StatePublished - Jan 1 2011


  • HIV therapy
  • pharmacogenetics
  • pharmacogenomics
  • workshop


Dive into the research topics of 'Pharmacogenomics of HIV therapy: Summary of a workshop sponsored by the National Institute of allergy and infectious diseases'. Together they form a unique fingerprint.

Cite this